Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer
Journal for ImmunoTherapy of Cancer · 2025
DOI: 10.1136/jitc-2025-012710 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Yuxin Yao und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Department of Thoracic Surgery, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Dendritic Cells, Immunotherapy, Protein Serine-Threonine Kinases, Oncogene Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Municipal Science Technology Commission, CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
LKB1 (STK11)-deficient tumors exhibit an immunosuppressive microenvironment that limits the efficacy of immunotherapies such as anti-programmed cell death protein 1 (PD-1) antibodies. However, the underlying mechanisms driving immune evasion remain unclear. Dendritic cells (DCs), especially conventional DC 1 (cDC1), play a crucial role in antigen presentation and CD8 + T-cell activation, yet their dysfunction in LKB1-deficient tumors has not been well characterized.
Methods
Tumor-intrinsic LKB1 deficiency was modeled by subcutaneous inoculation of CRISPR/Cas9-engineered Stk11 -knockout tumor cell lines into syngeneic mice. DC infiltration and function were assessed through a series of flow cytometry-based in vivo and in vitro assays, including analyses of infiltration, migration, antigen uptake, maturation, and CD8 + T-cell priming. Naïve CD8 + T-cell activation by cDC1s was evaluated via adoptive transfer of CD45.1 + OT-I T cells. Secretome proteomics and functional rescue experiments identified anterior gradient 2 (AGR2) as a key immunosuppressive mediator, and arginase 1 (ARG1) was validated as its functional interactor through liquid chromatography-tandem mass spectrometry (LC-MS/MS), co-immunoprecipitation, and imaging flow cytometry. Upstream regulation of AGR2 was investigated by AMPKα/FOXA1 silencing and chromatin immunoprecipitation (ChIP) quantitative PCR, revealing a tumor-intrinsic AMPKα–FOXA1–AGR2 axis driving DC dysfunction.
Results
LKB1-deficient tumors exhibited significantly reduced cDC1 infiltration, and cDC1s were functionally impaired in antigen uptake, migration, and naïve CD8 + T-cell priming. AGR2, a secreted protein transcriptionally upregulated via the tumor-intrinsic AMPKα–FOXA1 pathway, was identified as a key mediator of DC dysfunction. Mechanistically, AGR2 interacted with ARG1, stabilizing its expression and promoting ARG1 accumulation in DCs. Restoring DC infiltration and activity through FLT3L-driven expansion and tumor-antigen–specific DC supplementation significantly enhanced the efficacy of anti-PD-1 treatment in LKB1-deficient lung adenocarcinoma models.
Conclusion
Our study identifies profound DC dysfunction—characterized by impaired antigen uptake, migration, and naïve CD8 + T-cell priming—as a key mechanism of immune evasion in LKB1-deficient tumors. This dysfunction is driven by tumor-secreted AGR2, which stabilizes ARG1 in DCs and suppresses CD8 + T-cell activation. Targeting the AMPKα–FOXA1–AGR2–ARG1 axis or restoring DC competence offers a promising strategy to enhance immunotherapy efficacy in LKB1-deficient subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Department of Thoracic Surgery, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China.
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, Ch…
- Beijing Jishuitan Hospital, Department of Orthopaedic Oncology Surgery; Beijing Research Institute of Traumatology and Orthopaedics, Capital Medical University, Beijing, China.
- National Center for Orthopedics, Capital Medical University, Beijing, China.
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Department of Thoracic Surgery; State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medic…
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Office for Cancer Diagnosis and Treatment Quality Control, Chinese Academy of Medical Sciences and Peking Union Medical College, Beiji…
Förderung
- Beijing Municipal Science Technology Commission
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
Zitieren
APA
Yao, Y., Luo, Y., Wang, Z., Yin, E., Liu, C., Zheng, S., Wang, X., Tang, X., Sun, N., & He, J. (2025). Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012710
Vancouver
Yao Y, Luo Y, Wang Z, Yin E, Liu C, Zheng S, et al. Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012710
BibTeX
@article{Yao2025,
author = {Yao, Yuxin and Luo, Yuejun and Wang, Zhanyu and Yin, Enzhi and Liu, Chengming and Zheng, Sufei and Wang, Xinfeng and Tang, Xiaoya and Sun, Nan and He, Jie},
title = {Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
doi = {10.1136/jitc-2025-012710}
}
EUVIMED